What kind of medicine is Sotorasibu (AMG 510), its mechanism of action and main indications?

Sotorasib (R&D code AMG 510, trade name Lumakras) is an oral small molecule targeted drug targeting KRAS G12C mutation, developed by Amgen (Amgen). KRAS mutation is one of the driver genes of various solid tumors, among which G12C mutation is more common in non-small cell lung cancer (NSCLC) and some colorectal cancers. In the past, KRAS mutations have long been considered an “undruggable” target, and the launch of sotorasib is regarded as a major breakthrough in this field.

Sotoraxib is an irreversible inhibitor that interacts withKRAS The cysteine residue (Cys12) of the G12Cmutant protein specifically binds and locks it in the inactive GDP binding state, thereby blocking the downstream activation of the KRAS signaling pathway. This mechanism effectively cuts off the key signals that drive tumor cell growth and division. Unlike chemotherapy or traditional multi-target inhibitors, it can precisely act on mutant proteins and reduce the impact on normal cells, thereby ensuring efficacy while reducing some unnecessary toxic and side effects.

In2021, the U.S.FDA accelerated approval of sotorasiib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer carrying the KRAS G12C mutation after at least one systemic therapy. In addition, sotoracib has also shown potential efficacy in a variety of KRAS G12C positive tumors such as colorectal cancer and pancreatic cancer. A number of clinical trials are currently underway to evaluate its application prospects in more tumor types.

The success of sotorasiib not only provides new treatment options for patients with KRAS G12C mutations, but also provides a new paradigm for targeting "undruggable" mutations. However, clinically, some patients will develop drug resistance after using it for a period of time, which may be related to KRAS secondary mutations or activation of bypass signals. In the future, strategies combining EGFR inhibitors, immunotherapy or chemotherapy are expected to extend the duration of efficacy and expand the number of beneficiaries. Overall, the advent of sotorasiib marks the official beginning of the era of KRAS targeted therapy.

Reference materials:https://www.drugs.com/